Payment overview · 2025
General Payments
$93.99
5 reported records · 5 companies
Healthcare provider profile · identity verified
Romi Trabolsky
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LONGS, SC · NPI 1548978737
Verified facts
What the public records show
CMS Open Payments records show Romi Trabolsky received $93.99 in general payments during 2025 across 5 reported records.
Abbott Laboratories accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.80 | 24.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.75 | 23.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.23 | 19.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.73 | 16.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.48 | 16.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $93.99 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 172 |
| Lisinopril | Lisinopril | 238 | 87 |
| Gabapentin | Gabapentin | 205 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 65 |
| Losartan Potassium | Losartan Potassium | 131 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 50 |
| Omeprazole | Omeprazole | 126 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 39 |
| Metformin Hcl Er | Metformin Hcl | 117 | 41 |
| Trazodone Hcl | Trazodone Hcl | 114 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 33 |
| Carvedilol | Carvedilol | 101 | 37 |
| Ozempic | Semaglutide | 93 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 26 |
| Metformin Hcl | Metformin Hcl | 83 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 25 |
| Furosemide | Furosemide | 73 | 31 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Potassium Chloride | Potassium Chloride | 69 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 69 | 23 |
| Allopurinol | Allopurinol | 68 | 21 |
| Glimepiride | Glimepiride | 62 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 25 |
| Famotidine | Famotidine | 61 | 25 |
| Ibuprofen | Ibuprofen | 61 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 13 |
| Simvastatin | Simvastatin | 53 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 22 |
| Eliquis | Apixaban | 47 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Rybelsus | Semaglutide | 46 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 19 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | 13 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Celecoxib | Celecoxib | 29 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 15 |
| Buspirone Hcl | Buspirone Hcl | 26 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Prednisone | Prednisone | 26 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Klor-Con | Potassium Chloride | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93.99 · 5 records | Abbott Laboratories | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, ImmunoCAP, Ozempic, Rybelsus, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error